Related Experiment Video
Updated: Jun 12, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Primary systemic chemotherapy for inflammatory breast cancer
Sarah Sinclair1, Sandra M Swain
1Department of Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract:
The advent of multimodality therapy for patients with inflammatory breast cancer (IBC), consisting of neoadjuvant chemotherapy, particularly taxanes, surgery, radiotherapy, and hormonal therapy, has improved survival. A pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer and IBC improves outcomes, which suggests that obtaining a pathologic complete response to neoadjuvant chemotherapy has prognostic significance. The benefit of high-dose chemotherapy has shown encouraging results; however, this approach needs to be prospectively evaluated and to date remains experimental. Vascular endothelial growth factor, a promoter of angiogenesis, is highly expressed in IBC, making the angiogenesis pathway an attractive therapeutic target. A better understanding of the complex biology of IBC is needed for the development of additional targeted agents to further improve outcomes for patients with this aggressive form of breast cancer.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Treatment Resistent Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
